Loading clinical trials...
Loading clinical trials...
Multi-modal Assessment of GABA Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam. This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as psychosis which includes conditions like schizophrenia, schizoaffective disorder, and mood disorders). The study will also enroll eligible participants without any psychiatric illness, to compare their brains. The study will require participants to have 3-4 sessions over a few weeks. The initial assessments (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the MRI. During the fMRI the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, women of child bearing potential will have a urine pregnancy test, vital signs taken, and asked to complete more qols.
* Please note the collaborator (NIMH) is requesting that an NCT number be obtained prior to receiving the award number. * Initial assessment(s) may be done via videoconference due to Covid.
Age
16 - 60 years
Sex
ALL
Healthy Volunteers
Yes
University of Michigan
Ann Arbor, Michigan, United States
Start Date
January 16, 2020
Primary Completion Date
February 28, 2025
Completion Date
February 28, 2025
Last Updated
March 13, 2025
143
ACTUAL participants
Placebo and fMRI
OTHER
Lorazepam and fMRI
DRUG
Lead Sponsor
University of Michigan
Collaborators
NCT00090662
NCT06716502
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06290258